
Agilent (A) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.
| Revenue (TTM) | $7.37B |
| Gross Profit (TTM) | $3.96B |
| EBITDA | $2.08B |
| Operating Margin | 25.60% |
| Return on Equity | 21.00% |
| Return on Assets | 8.63% |
| Revenue/Share (TTM) | $26.10 |
| Book Value | $26.11 |
| Price-to-Book | 5.74 |
| Price-to-Sales (TTM) | 5.77 |
| EV/Revenue | 6.03 |
| EV/EBITDA | 21.85 |
| Quarterly Earnings Growth (YoY) | 8.50% |
| Quarterly Revenue Growth (YoY) | 8.10% |
| Shares Outstanding | $281.97M |
| Float | $280.96M |
| % Insiders | 0.20% |
| % Institutions | 95.58% |
Volatility is currently expanding

Agilent (A) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the U.S. launch of the Agilent S540MD Slide Scanner System, a whole slide imaging (WSI) digital scanner, following FDA clearance. This launch underscores Agilent's ongoing commitment to digital pathology, broadening its portfolio to address the increasing demand for high-throughput solutions in clinical laboratories.Pathology laboratories continue to face increasing pressure to improve diagnostic efficiency.

Explore how Agilent's (A) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Agilent Technologies is upgraded to Buy after a strong Q3 2026, with revenue up 8% and EPS up 18% YoY. All three segments posted robust growth, notably Life Sciences and Diagnostics, which saw operating margin jump nearly 600 bps to 23.5%. Guidance for Q4 and FY26 implies continued momentum, with management projecting 6.5–7.5% revenue growth and 8.5% EPS growth for Q4.

Agilent Technologies, Inc. (A) Q3 2026 Earnings Call Transcript

Agilent Technologies raised its annual profit forecast on Wednesday, betting on improving demand for its medical tools and equipment used in lab research and drug development.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.88 billion for the third quarter ended July 31, 2026, representing growth of 8.1% reported and up 7.3% core(1) compared with the third quarter of fiscal year 2025. Third-quarter GAAP net income was $362 million, or $1.28 per share. This compares with $336 million, or $1.18 per share, in the third quarter of fiscal year 2025. Non-GAAP net income(3) was $459 million (including a $17 million net.

Does Agilent Technologies (A) have what it takes to be a top stock pick for momentum investors? Let's find out.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Agilent (A), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended July 2026.

Agilent Technologies (NYSE:A | A Price Prediction) heads into a pivotal earnings setup for retirement-oriented portfolios, with a company-confirmed Q3 2026 report after the close on Aug.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on A and any ticker you trade — then tracks every position and per-strategy win rate.